Over the past five years, the cosmetic industry has met with several legislative changes. Within the new legislative package, including the new REACH and CLP, it is important to find a comfortable routine that will minimize costs while staying effective and compliant with all regulations.
Topic insight: Implementation of EU-GMP Annex 16 at H. Lundbeck
Starting the project with a GAP analysis revealed that a number of Lundbeck’s procedures would have to be updated in order to be in compliance with the requirements of the revised annex 16. The main focus areas would be certificates, quality agreements and education of our personnel.
Certificates are a challenge, since our electronic solution requires a generic approach, and affiliates both inside and outside the EU have their own requirements. Quality agreements must describe in more detail the division of responsibility between QP’s inside the EU; if outside the EU, additional requirements apply. Furthermore, a system had to be implemented insuring that all relevant knowledge is available to the pharmacist (QP delegate) when releasing product.
At Lundbeck, these requirements are facilitated by our creation of “Quality Responsible Persons”, which in our terminology means a person within Quality Assurance who is appointed as the main expert of a business area. E.g., tablet production at HQ, or CMO production worldwide. The “Quality Responsible Person” reports directly to the QP on all compliance issues within his area. At the same time, the “Quality Responsible Person” is in charge of the PQR process within the business area and is responsible for keeping the other pharmacists (QP delegates) updated on all relevant matters regarding product and procedure.
In each business area, a “Risk Register” is established and maintained through cooperation between the “Quality Responsible Person” and a representative from that business area.
The purpose of the “Risk Register” is to mitigate all risk by stating the problem and its impact, thereby enabling prioritization based on facts and facilitating the implementation process.
Each business area, e.g., sterile production at HQ, packaging at HQ and so forth, is evaluated monthly in a management report. A “Quality Index” generated by Quality Assurance addresses relevant parameters for the specific business area. It is typically influenced by parameters such as deviations or rejected batches, but it is also linked to the “Risk Register”, and management is thereby involved directly in the prioritization and risk mitigation.
The implementation of EU-GMP Annex 16 at Lundbeck was facilitated by these processes.
Interested in this topic?
Advanced Protein Aggregation & Characterization
This training will focus on occurrence of particles in drug products, effects of protein aggregates, critical process and parameters. Attendees will gain overview of on utility and limits of predictive experiments, learn concerns from the authorities and relevant aggregation guidelines, and more.
CMC Analytical Comparability: Methods & Strategies for Biologics, Biosimilars & Biobetters
Attendees will be introduced to comparability in biosimilar development, the analytical strategies of protein characterization of biosimilars, the structure of proteins, in vitro pharmacology and much more.
Corporate Compliance & Transparency in the Pharmaceutical Industry
This two-day conference will serve as a platform for an open and dynamic dialogue with HCPs and patients to achieve common goals. Learn how to embed compliance in the business and develop one simple system for managing compliance & transparency in a complex and regulated environment.
Driving the national agenda of Medical tourism through PX Excellence
Read the interview with Dr. Layla Al-Marzouqi, Director of Medical Tourism Council at Dubai Health Authority, and learn how to enrich patient experience and quality of healthcare.
No more trouble with dangerous good shipments
Global temperature controlled pharmaceutical shipments are constantly faced with new logistics challenges and regulations. This January 2017, IATA Dangerous Goods Regulations added further complexity to shipping cold chain products compliantly.
5 Changes in Signal Detection Management
The European Medicines Agency, regulatory authorities in the Member States and marketing authorisation holders are responsible for detecting and managing safety signals. A safety signal is generally defined as information about a new or known Adverse Event that may have been caused by a medicine, where it is therefore necessary to conduct further investigation. Evaluation of safety signals plays a major role within pharmacovigilance. Therefore, it is vital for regulatory authorities to know the latest updates detailing the risks and benefits of medicines. The EudraVigilance database is an important source of information on suspected adverse reactions and signals.